In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and live reporting from the San Francisco conference, join our newsletter list.
After a one-day respite from JPM tradition, the rain returned this morning, leading to some dampened spirits and at least one canny promotional effort. (We’ve still got plenty of STAT-branded umbrellas at our coworking space, if you’re in need.) Anyway, here are the highlights from Day 2.
Will Sarepta earn a participation trophy from the FDA?
Sure seems like it, based on remarks made by Peter Marks, the agency’s chief gene therapy regulator, at STAT’s event on Monday night. By trophy, we mean full approval of some kind for Elevidys, Sarepta Therapeutics’ treatment for Duchenne muscular dystrophy.
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect